Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2765578 | 0.89 | CYP19A1 (0.35) | CYP19A1 | |
| Butadiene SCHEMBL2764921 | 0.85 | KDM5A (0.37) | KDM5AKDM4CKDM5BKCNH2CYP19A1 | |
| SCHEMBL2765813 | 0.82 | — | — | |
| SCHEMBL2455162 | 0.81 | CYP19A1 (0.39) | KDM5AKDM4CKDM5BCYP19A1NOS2 | |
| SCHEMBL2765752 | 0.77 | CYP4F2 (0.44) | KDM5AKDM4CKDM5BKCNH2CYP19A1 | |
| SCHEMBL2764224 | 0.75 | TLR7 (0.31) | TLR7NOS2 | |
| SCHEMBL26048236 | 0.75 | KCNH2 (0.44) | KDM5AKDM4CKDM5BKCNH2CYP19A1 | |
| SCHEMBL26040144 | 0.74 | KCNH2 (0.47) | KDM5AKDM4CKDM5BKCNH2CYP19A1 | |
| Butadiene SCHEMBL2766098 | 0.74 | CYP19A1 (0.34) | CYP19A1 | |
| SCHEMBL26040583 | 0.74 | KCNH2 (0.47) | KDM5AKDM4CKDM5BKCNH2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266911-B1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-6881802-B2 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | KDM5A 2073/4885KDM4C 1819/4885KDM5B 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.